Sermorelin is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH) that signals your own pituitary gland to produce and release growth hormone, rather than supplying growth hormone from outside the body. Because it works with the body’s existing feedback system, it produces the kind of pulsed release the gland is designed to make. It is prescribed today as a compounded medication through licensed pharmacies, and it sits inside both men’s and women’s restoration protocols with equal relevance.
That last point matters. The growth-hormone axis is not a men’s-only system, and sermorelin is not a men’s-only tool. What follows is a plain-language read on the biology, the regulatory history, and where sermorelin reasonably fits — without the certainty that the category’s marketing usually claims.
What is sermorelin?
Sermorelin corresponds to the first 29 amino acids of human growth-hormone-releasing hormone. GHRH itself is 44 amino acids long, but the (1-29) fragment retains essentially the full biological activity of the parent molecule (Sermorelin, Wikipedia; Prakash & Goa, 1999, PubMed 18031173). In other words, it is a compact, working copy of the natural signal the hypothalamus uses to tell the pituitary to release growth hormone.
The important distinction is that sermorelin is a secretagogue — a molecule that causes a gland to secrete its own hormone. It does not contain growth hormone. It asks the pituitary to make and release growth hormone on the body’s own terms.
How does sermorelin work?
Sermorelin binds to GHRH receptors on the somatotroph cells of the anterior pituitary. That binding activates adenylyl cyclase, raises intracellular cyclic AMP, and prompts the synthesis and release of growth hormone from the gland’s storage granules (mechanism review, DrOracle).
Two features of that mechanism are worth understanding, because they define the whole approach:
It preserves pulsatile release. The body does not secrete growth hormone in a steady stream; it releases it in discrete pulses, mostly overnight. Sermorelin has a short half-life by design, so it produces a discrete pulse rather than a sustained elevation — closer to the cadence the system already runs on.
It preserves negative feedback. Growth-hormone output is held in check by somatostatin, the body’s own braking hormone. Because sermorelin works upstream of the pituitary rather than replacing its output, that brake stays intact. This is why the mechanism is described as self-limiting: the body retains the ability to say “enough.”
How is sermorelin different from growth hormone injections?
This is the question most people are actually asking. Recombinant human growth hormone (rhGH) supplies the finished hormone directly, overriding the gland’s own production and its feedback loops. Sermorelin instead works through the existing architecture — it prompts the pituitary, and the pituitary’s normal regulation still applies.
It is the same distinction that separates a precursor from a finished molecule elsewhere in restoration medicine — much like the difference between NAD+ and its precursors NMN and NR, where one supplies the end-product directly and the other works through the body’s own conversion.
The practical consequence is a different safety and control profile. Because sermorelin depends on a functioning pituitary and remains subject to somatostatin feedback, it is structurally harder to push the system past its own limits than it is with direct hormone administration. That is a design difference, not a promise of outcomes — and it is the reason clinicians frame sermorelin as the more measured entry point into the growth-hormone conversation.
Is sermorelin FDA-approved?
The honest answer is layered, and worth stating precisely.
Sermorelin was previously sold as an FDA-approved branded drug called Geref, manufactured by Serono, and used to diagnose and treat growth-hormone deficiency, including in children with growth failure. The manufacturer discontinued production in 2008 and asked the FDA to withdraw the approvals; marketing approval was formally withdrawn in 2009.
Critically, the discontinuation was a commercial decision, not a safety one. As recombinant growth hormone became the dominant treatment for significant pediatric deficiency, the market for sermorelin shrank and production was no longer commercially viable. The FDA made this explicit in a 2013 Federal Register determination stating that Geref injection was not withdrawn from sale for reasons of safety or effectiveness (Federal Register, 2013).
That determination is what allows sermorelin to remain available today as a compounded medication, prepared by state-licensed pharmacies under federal and state compounding frameworks and dispensed by prescription. A compounded medication is not an FDA-approved finished product, and that distinction should always be visible to the patient.
What does the evidence actually show?
The strongest human evidence for sermorelin is in the setting it was originally approved for: as a diagnostic agent for the growth-hormone axis and in the treatment of children with idiopathic growth-hormone deficiency (Prakash & Goa, 1999, PubMed 18031173). In that context, its ability to stimulate growth-hormone release is well characterized.
Its contemporary use — supporting the growth-hormone axis in adults who are paying attention to age-related decline — is off-label, and the human outcome data for that use is earlier-stage than the marketing around it suggests. The mechanism is sound and biologically plausible; the claim that it produces specific, durable results in healthy adults is not settled science. A fair reading is that sermorelin is a physiologically reasonable way to support a declining axis, best treated as a measured protocol you verify rather than a promised outcome.
Who is sermorelin a reasonable choice for?
Sermorelin fits adults — men and women alike — who want to support the growth-hormone axis in a calibrated way and are willing to measure the result rather than assume it. Because the axis declines with age in both sexes, the tool is genuinely bilateral, not a men’s-performance product with a women’s footnote.
It is most reasonable when it is anchored to bloodwork: a baseline panel (including IGF-1, the downstream marker of growth-hormone activity) before starting, and a follow-up to see whether the marker actually moves. That measurement is what turns a protocol into a decision — the same measure-first logic we apply to the question of whether NAD+ is worth it.
Sermorelin is not appropriate during pregnancy or nursing, in the presence of an active malignancy without oncologist clearance, or for anyone with a known pituitary tumor. Any restoration protocol should be prescribed and supervised within a licensed clinical relationship, with the contraindications reviewed against your own history.
How Trellis approaches sermorelin
Trellis Vitality is built as the accessibly-priced, patient-first alternative to premium-gated longevity clinics — the same clinical rigor, delivered on-demand and at home, without the five-figure annual membership. Sermorelin is offered as a flat monthly subscription inside that model, prescribed through a licensed clinical flow and dispensed by a compounding pharmacy.
Every new protocol begins with a free Vitality Lab Kit and a first protocol, so the decision to start — and to continue — is anchored to your own biomarkers rather than to a testimonial. We do not run discount codes; the value is in the measurement and the supervision, not a countdown timer. If you’re still comparing your options, our roundup of the top longevity telehealth clinics for 2026 lays out the landscape.
Sermorelin is prescribed and compounded by a state-licensed, FDA-regulated compounding pharmacy. Compounded medications are not FDA-approved as finished products, and nothing here is a promise of results. Use is decided within a licensed clinical relationship.
Sermorelin FAQ
Is sermorelin the same as growth hormone? No. Sermorelin does not contain growth hormone. It is a GHRH analog that prompts your own pituitary to make and release growth hormone, so the body’s own regulation still applies.
Is sermorelin FDA-approved? Its former branded version (Geref) was FDA-approved and then discontinued in 2008 for business reasons — the FDA confirmed in 2013 it was not withdrawn for safety or effectiveness. It is available today as a compounded medication by prescription, which is not an FDA-approved finished product.
Can you overdose on sermorelin the way you can on growth hormone? The mechanism is self-limiting: it depends on a working pituitary and remains subject to somatostatin feedback, so it is structurally harder to push past the body’s own limits than with injected growth hormone. That is a design difference, not a promise, and dosing is still clinician-supervised.
Is sermorelin only for men? No. The growth-hormone axis declines with age in both men and women, and sermorelin applies to both. Trellis treats it as a bilateral restoration tool.
How would I know if sermorelin is working? Anchor on a baseline panel including IGF-1 before starting, then re-test. That lets you judge the protocol on whether your markers move, not on marketing or anecdote.
The measured way to decide is to look at your own numbers first. Begin your assessment →
Sources
- Sermorelin — overview and GHRH (1-29) structure. Wikipedia. https://en.wikipedia.org/wiki/Sermorelin
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. PubMed 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/
- Mechanism of action of sermorelin (GHRH analogue). DrOracle. https://www.droracle.ai/articles/158705/what-is-the-mechanism-of-action-of-sermorelin-growth
- Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register, March 4, 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams